According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

Palivizumab, when given through the veins or into a muscle (systemically), reduces hospitalisations due to respiratory syncytial virus (RSV) and reduces respiratory problems later on (chest wheezing), ...

French pharmaceutical and healthcare company Sanofi has agreed to buy the British biotechnology firm Vicebio for up to $1.6bn ...

Hendra virus is a highly lethal zoonotic pathogen primarily transmitted from flying foxes to horses and occasionally humans, ...

Two recent studies published this week assess the low uptake of respiratory syncytial virus (RSV) vaccine among US veterans and examine the risk factors for intensive care unit (ICU) admission and ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory ...

Winter is here, and with it come higher rates of respiratory illnesses. If you've been struck down recently with a sore ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

Vermont has the second lowest state fatality rate in the US (148.4 per 100K; Hawaii 113.7/100K). Mississippi (466/100K) and ...

Vicebio Ltd, a biopharmaceutical company developing novel vaccines, has entered an exclusive, definitive agreement to be ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...